Seeking Alpha

AstraZeneca wins $76M in Prilosec generic case

  • Canada's Apotex must pay AstraZeneca (AZN -0.1%) $76M in damages tied to the generic drug maker's sale of generic Prilosec.
  • The award amounts to 50% of the profits Apotex earned selling the drug over three-and-a-half years.
  • The patent infringement portion of the case was already decided (in 2007) and thus only the judgement amount is new.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: